Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, schizophrenia, diabetes, ADHD and chronic migraine.

Latest News

Jul 7, 2014
Heptares Announces Publication In Nature Of First Structure Of Metabotropic Glutamate Receptor 5 Transmembrane Domain
Jun 30, 2014

Heptares Chief Scientific Officer And Co-founder Fiona Marshall to Present At Royal Society Of Medicine Medical Innovations Summit

Events

Aug 10-14, 2014
ACS
San Francisco, CA, USA
Presenting: Dahlia Weiss, Steve Andrews

Sep 7-11, 2014
EFMC-ISMC
Lisbon, Portugal
Presenting: Jon Mason

© 2012-2014 Heptares Therapeutics